Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer
Conclusion: High CCNE1 levels were confirmed as a biomarker of resistance to letrozole+palbociclib. Ki67 recovery within 3-9 days of discontinuing palbociclib indicates incomplete suppression of proliferation during the "off" week of its schedule.PMID:34645649 | DOI:10.1158/1078-0432.CCR-21-1628
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Mitch Dowsett Lucy Kilburn Mothaffar F Rimawi C Kent Osborne Katherine Pogue-Geile Yuan Liu Samuel A Jacobs Melanie Finnigan Shannon Puhalla Andrew Dodson Vera Martins Maggie Cheang Sophie Perry Chris Holcombe Nicholas C Turner Claire Swift Judith M Bliss Source Type: research